1.
Arch Dermatol Res
; 313(2): 127-128, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1064476
Subject(s)
COVID-19/complications , Cytokine Release Syndrome/prevention & control , Practice Guidelines as Topic , Psoriasis/drug therapy , Withholding Treatment/standards , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Biological Factors/administration & dosage , Biological Factors/adverse effects , COVID-19/epidemiology , COVID-19/immunology , COVID-19/virology , Clinical Decision-Making , Comorbidity , Cytokine Release Syndrome/immunology , Dermatology/standards , Dose-Response Relationship, Drug , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Patient Selection , Psoriasis/epidemiology , Psoriasis/immunology , Risk Assessment , Risk Factors , SARS-CoV-2/immunology , Societies, Medical/standards , Thalidomide/administration & dosage , Thalidomide/adverse effects , Thalidomide/analogs & derivatives
2.
J Eur Acad Dermatol Venereol
; 34(12): e770-e772, 2020 Dec.
Article
in English
| MEDLINE | ID: covidwho-691174